National Bank of Canada FI reduced its stake in shares of Laboratory Co. of America Holdings (NYSE:LH – Free Report) by 12.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,802 shares of the medical research company’s stock after selling 6,800 shares during the quarter. National Bank of Canada FI owned approximately 0.06% of Laboratory Co. of America worth $10,976,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in LH. Provence Wealth Management Group purchased a new stake in shares of Laboratory Co. of America during the third quarter worth about $29,000. Mendota Financial Group LLC acquired a new position in Laboratory Co. of America during the 4th quarter valued at approximately $29,000. Tradewinds Capital Management LLC purchased a new position in shares of Laboratory Co. of America in the third quarter worth $34,000. Bruce G. Allen Investments LLC acquired a new stake in shares of Laboratory Co. of America during the fourth quarter worth $60,000. Finally, Disciplined Equity Management Inc. purchased a new stake in shares of Laboratory Co. of America during the fourth quarter valued at $68,000. Hedge funds and other institutional investors own 95.94% of the company’s stock.
Insider Buying and Selling at Laboratory Co. of America
In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 237 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $226.45, for a total transaction of $53,668.65. Following the completion of the sale, the executive vice president now owns 7,637 shares of the company’s stock, valued at $1,729,398.65. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CAO Peter J. Wilkinson sold 2,439 shares of the firm’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $204.33, for a total transaction of $498,360.87. Following the completion of the transaction, the chief accounting officer now directly owns 2,087 shares in the company, valued at approximately $426,436.71. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 237 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $226.45, for a total transaction of $53,668.65. Following the sale, the executive vice president now owns 7,637 shares in the company, valued at $1,729,398.65. The disclosure for this sale can be found here. Insiders have sold 56,985 shares of company stock worth $12,302,964 in the last ninety days. 0.85% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on LH
Laboratory Co. of America Price Performance
Shares of Laboratory Co. of America stock opened at $201.61 on Thursday. The business has a 50 day simple moving average of $209.55 and a two-hundred day simple moving average of $214.89. The company has a debt-to-equity ratio of 0.39, a current ratio of 0.88 and a quick ratio of 0.76. The stock has a market capitalization of $17.00 billion, a P/E ratio of 40.57, a PEG ratio of 1.51 and a beta of 1.02. Laboratory Co. of America Holdings has a 12 month low of $174.20 and a 12 month high of $234.09.
Laboratory Co. of America (NYSE:LH – Get Free Report) last released its earnings results on Thursday, April 25th. The medical research company reported $3.68 earnings per share for the quarter, topping analysts’ consensus estimates of $3.48 by $0.20. The business had revenue of $3.18 billion for the quarter, compared to analyst estimates of $3.12 billion. Laboratory Co. of America had a net margin of 3.52% and a return on equity of 14.68%. The business’s revenue was up 4.6% on a year-over-year basis. During the same period last year, the company posted $3.82 EPS. As a group, analysts predict that Laboratory Co. of America Holdings will post 14.87 EPS for the current fiscal year.
Laboratory Co. of America Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 12th. Shareholders of record on Tuesday, May 28th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.43%. The ex-dividend date of this dividend is Tuesday, May 28th. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 57.95%.
About Laboratory Co. of America
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).
Read More
- Five stocks we like better than Laboratory Co. of America
- Stock Splits, Do They Really Impact Investors?
- 3 Tripe-Digit Growth Mid Cap Stocks to Watch This Quarter
- How to Invest in Insurance Companies: A Guide
- Has FMC Stock Reached Bottom? First Quarter Earnings Say Yes
- What is the FTSE 100 index?
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Co. of America Holdings (NYSE:LH – Free Report).
Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.